News

Shares of Novavax, Inc. (NVAX) plunged over 19.5% on Thursday after Health and Human Services Secretary Robert F. Kennedy Jr.
By Kamal Choudhury (Reuters) -Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and ...
The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on ...
Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...
Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay.
Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...
Novavax started the week hoping the FDA would issue a full approval of its Covid vaccine. But the decision never came.
The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has ...
Shuren, who retired from his spot leading the FDA’s Center for Devices and Radiological Health (CDRH) in 2024, said last week ...
The delay dovetails with moves by Republican lawmakers in at least 7 states to ban or limit mRNA vaccines. HealthDay News — The US Food and Drug Administration (FDA) has delayed the full ...
The agency is sitting on a decision to grant full approval for Novavax’s shot, days after top vaccine regulator pushed out.